University of Connecticut Health Center CAROLE AND RAY NEAG COMPREHENSIVE CANCER CENTER
Welcome,         Profile    Billing    Logout  
 1 Trial 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sampson, Christopher T
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
82
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
07/26
12/26

Download Options